Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesoPher and Mitazalimab in Metastatic Pancreatic Cancer
NCT05650918Phase 1Completed
- Start
- Aug 2021
- Primary completion
- May 2023
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitazalimab and MesoPher. Primary endpoint: Incidence of Dose Limiting Toxicities at 6 weeks. Started Aug 2021; status: completed.
02
Drugs
mitazalimabMesoPher
Beyond the preview
Go deeper on NCT05650918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650918.